1 2 Bentley, K. W.; Hardy, D. G. (1967). “Novel analgesics and molecular rearrangements in the morphine-thebaine group. 3. Alcohols of the 6,14-endo-ethenotetrahydrooripavine series and derived analogs of N-allylnormorphine and -norcodeine”. Journal of the American Chemical Society. 89 (13): 3281–3292. doi:10.1021/ja00989a032. PMID6042764.
↑ Martin, T. J.; Hairston, C. T.; Lutz, P. O.; Harris, L. S.; Porreca, F. (1998). “Anti-allodynic actions of intravenous opioids in the nerve injured rat: Potential utility of heroin and dihydroetorphine against neuropathic pain”. European Journal of Pharmacology. 357 (1): 25–32. doi:10.1016/S0014-2999(98)00531-7. PMID9788770.
↑ Lewis, J. W.; Husbands, S. M. (2004). “The orvinols and related opioids--high affinity ligands with diverse efficacy profiles”. Current Pharmaceutical Design. 10 (7): 717–732. doi:10.2174/1381612043453027. PMID15032698.
↑ Ohmori, S.; Morimoto, Y. (2002). “Dihydroetorphine: a potent analgesic: pharmacology, toxicology, pharmacokinetics, and clinical effects”. CNS Drug Reviews. 8 (4): 391–404. doi:10.1111/j.1527-3458.2002.tb00236.x. PMID12481194.
↑ Gerak, L. R.; Gauthier, C. R.; France, C. R. (2003). “Discriminative stimulus and antinociceptive effects of dihydroetorphine in rhesus monkeys”. Psychopharmacology. 166 (4): 351–359. doi:10.1007/s00213-002-1268-y. PMID12601499.
↑ Husbands, S. M.; Lewis, J. W. (2003). “Opioid ligands having delayed long-term antagonist activity: potential pharmacotherapies for opioid abuse”. Mini Reviews in Medicinal Chemistry. 3 (2): 137–144. doi:10.2174/1389557033405395. PMID12570846.
